IO-veckan 2024: Rechallenge patients with immune checkpoint inhibitors following high grade adverse events?

2024 October. Time 45:00.
Webinar broadcasted October 9^th

During the webinar, following studies are mentioned:

• Atkins MB. et al. JCO, 2023;41(2) 186-197, Combination Dabrafenib and Trametinib vs Combination Nivolumab and Ipilimumab for Pts With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134.
• Yochum, Z. et al. The Lancet, 2024;404 (10460) 1290-1282, Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma.
• Papathanassiou M. et al. Front. Oncol. 2023 12:996553, Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis.

Invited speaker: James Larkin, Professor, Consultant Medical Oncologist

Professor James Larkin is a Medical Oncologist who specialises in the treatment of melanoma and cancers of the kidney. Following his clinical training in Oxford and London, he undertook a medical research followship and PhD at the Institute of Cancer Research. His specialist training took place at The Royal Marsden, London, where he was appointed as consultant in 2008. Professor Larkin’s research interests involve understanding cancer and its consequences better, as well as developing improved treatments, particularly with targeted therapies and immunotherapies.

Moderator: Fernanda Costa Svedman, Senior Physician Fernanda Costa Svedman is senior physician in oncology at Karolinska University Hospital. Her clinical work focuses on melanoma and GU cancer and research-wise is biomarkers her main focus.

OCT 2024 ONC-SE-2400076